CTRN
Citi Trends, Inc.
CTRN has the edge over LCID overall, supported by lower modeled downside and stronger modeled upside.
LCID
Lucid Group, Inc.
LCID offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CTRN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Stable | |
| Strong |
CTRN's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CTRN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.8x | $3.31 | -92% |
| Fair | 10x | $8.73 | -80% |
| Forward | 19x | $43.05 | — |
| Expensive | 46x | $39.40 | -8.5% |
| Current | 50x | $43.05 | — |
Historical ranges are pointers, not guarantees.
CTRN's PE is in its expensive range at 50x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its fair range.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
CTRN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CTRN, with profitability improving.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CTRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.33 | +170% |
| Q3 2026 | $0.86 | +$2.85 |
| Q2 2026 | $1.43 | +$6.09 |
| Q1 2026 | $0.63 | +$5.82 |
| Q4 2025 | -$1.99 | +$1.07 |
| Q3 2025 | -$1.99 | +$0.68 |
| Q2 2025 | -$4.66 | -$3.59 |
| Q1 2025 | -$5.19 | -$3.73 |
| Q4 2024 | -$3.06 | -$2.04 |
CTRN has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
CTRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $211.6M | +11% |
| Q2 2026 | $230.9M | +14% |
| Q1 2026 | $230.4M | +9.1% |
| Q4 2025 | $197.1M | +10% |
| Q3 2025 | $190.8M | +8% |
| Q2 2025 | $201.7M | +8.3% |
| Q1 2025 | $211.2M | -1.9% |
| Q4 2024 | $179.1M | -0.3% |
CTRN's revenue is recovering but still below its 2021 peak: $212M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | -2.7 points |
| Q2 2026 | 3.2% | +3 points |
| Q1 2026 | 3.1% | +2.6 points |
| Q4 2025 | -3.7% | +1.2 points |
| Q3 2025 | 1.8% | +16 points |
| Q2 2025 | 0.2% | +4 points |
| Q1 2025 | 0.6% | -1.3 points |
| Q4 2024 | -4.9% | -1.6 points |
CTRN has the edge over LCID on profitability, with a higher operating margin.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over CTRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
CTRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24M | -$22.2M |
| Q2 2026 | $15M | +$28.1M |
| Q1 2026 | $14.7M | -44% |
| Q4 2025 | $767K | +$21.2M |
| Q3 2025 | -$1.7M | -205% |
| Q2 2025 | -$13.1M | +$8.1M |
| Q1 2025 | $26M | +30% |
| Q4 2024 | -$20.4M | -$12.8M |
CTRN has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
CTRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.5% | -301K shares |
| 1 year | -1.6% | -130K shares |
| 3 years | -0.5% | -41.4K shares |
| 5 years | -11% | -995K shares |
| Available history | -30% | -3.5M shares |
CTRN has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $6.3M |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | $4.7M |
| Q2 2022 | $5.3M |
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
CTRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.2x | Net Cash |
| Q2 2026 | -2.7x | Net Cash |
| Q1 2026 | -3.0x | Net Cash |
| Q4 2025 | -3.2x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2024 | -27.2x | Net Cash |
| Q4 2023 | -20.2x | Net Cash |
| Q3 2023 | -1.6x | Net Cash |
CTRN has more cash than debt.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CTRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.5 | Neutral |
| Stochastic | 6.0 | Oversold |
CTRN's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CTRN PE vs Consumer Cyclical Sector
| Metric | CTRN | Sector median | Relative |
|---|---|---|---|
| PE | 50x | 18x | 178% above |
| PE % | 86 | 47 | 39 pts above |
CTRN is trading at 50x earnings, a 178% premium to the Consumer Cyclical sector's median of 18x.
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
CTRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.4 | 9.1% below |
| 20 week MA | $57.9 | 26% below |
| 50 week MA | $50.8 | 15% below |
| 100 week MA | $40.1 | 7.4% above |
| 200 week MA | $31.2 | 38% above |
CTRN has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
CTRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.8 | $47.4 | +108% |
| 2021 | $47.4 | $76.4 | +61% |
| 2022 | $76.4 | $27.6 | -64% |
| 2023 | $27.6 | $28.3 | +2.4% |
| 2024 | $28.3 | $26.9 | -5.1% |
| 2025 | $26.9 | $40.2 | +50% |
| 2026 YTD | $40.2 | $43.1 | +7.2% |
CTRN has the edge over LCID on returns for 2026, with the stronger performance.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.